KarXT Emerging

“KarXT (xanomeline–trospium) Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about KarXT (xanomeline–trospium) for Schizophrenia and Alzheimer’s Disease Psychosis (ADP) in the seven major markets. A detailed picture of the KarXT (xanomeline–trospium) for schizophrenia and Alzheimer’s disease psychosis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019–2032 is provided in this report along with a detailed description of the KarXT (xanomeline–trospium).

The report provides insights into the mechanism of action, dosage, administration, research, and development, including regulatory milestones and other developmental activities. Further, it also consists of future market assessments, including the KarXT (xanomeline–trospium) market forecast analysis for schizophrenia and Alzheimer’s disease psychosis in the 7MM, SWOT, analysts’ views, a comprehensive overview of market competitors, and a brief about other emerging therapies in schizophrenia and Alzheimer’s disease psychosis.

Drug Summary

KarXT (xanomeline–trospium), developed by Karuna Therapeutics, is an oral, investigational M1/M4-preferring muscarinic agonist for treating psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease. It is the first potential medicine with a unique dual mechanism that does not rely on the dopaminergic or serotonergic pathway to treat symptoms of serious mental illness.

KarXT combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist that does not measurably cross the blood–brain barrier, confining its effects to peripheral tissues, to preferentially stimulate muscarinic receptors in the central nervous system (CNS) and unlock the therapeutic potential of xanomeline while ameliorating its side effects. The activity at M1 and M4 receptors indirectly affects dopamine neurotransmission in brain regions that mediate symptoms of serious mental illness, such as psychosis in Alzheimer’s disease and the positive, negative, and cognitive symptoms of schizophrenia.

Karuna Therapeutics has submitted the new drug application (NDA) for KarXT to the US FDA for treating schizophrenia. Further, the drug is undergoing multiple Phase III clinical trials, including EMERGENT-4 and EMERGENT-5, to evaluate the long-term safety of KarXT as a monotherapy; topline data from these trials are expected by 2024. KarXT is also being investigated in the Phase III trial, ARISE study, as adjunctive therapy in subjects with inadequately controlled symptoms of schizophrenia; the topline data of this study is expected by the second quarter of 2024.

KarXT is undergoing two Phase III trials, ADEPT-1, in subjects with psychosis associated with Alzheimer’s disease, whose topline data is expected by 2025. Additionally, an open-label Phase III extension study, ADEPT-3, is ongoing to assess the long-term safety and tolerability of karXT in subjects with psychosis associated with Alzheimer’s disease. Moreover, the company planned to initiate ADEPT-2 in the second quarter of 2023, whose data is also anticipated by 2025.

Scope of the Report

The report provides insights into the following:

• A comprehensive product overview including the KarXT (xanomeline–trospium) description, mechanism of action, dosage and administration, and research and development activities in schizophrenia and Alzheimer’s disease psychosis.
• Elaborated details on KarXT (xanomeline–trospium) regulatory milestones and other development activities have been provided in this report.
• The report also highlights the KarXT (xanomeline–trospium) research and development activities in schizophrenia and Alzheimer’s disease psychosis across the US, EU4 and the UK, and Japan.
• The report contains forecasted sales of KarXT (xanomeline–trospium) for schizophrenia and Alzheimer’s disease psychosis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for schizophrenia and Alzheimer’s disease psychosis.
• The report also features the SWOT analysis with analyst views for KarXT (xanomeline–trospium) in schizophrenia and Alzheimer’s disease psychosis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research, and in-house analysis by DelveInsight’s industry experts. Information and data from secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals, and access to available databases.

KarXT (xanomeline–trospium) Analytical Perspective by DelveInsight

In-depth KarXT (xanomeline–trospium) market assessment

This report provides a detailed market assessment of KarXT (xanomeline–trospium) for schizophrenia and Alzheimer’s disease psychosis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This report segment provides forecasted sales data for KarXT (xanomeline–trospium).

KarXT (xanomeline–trospium) clinical assessment

The report provides the clinical trial information of KarXT (xanomeline–trospium) for schizophrenia and Alzheimer’s disease psychosis, covering trial interventions, trial conditions, trial status, and start and completion dates.

Report Highlights 

• In the coming years, the market scenario for schizophrenia and Alzheimer’s disease psychosis is set to change due to the extensive research and incremental healthcare spending worldwide; this would expand the market size to enable drug manufacturers to penetrate more into the market.  
• The companies are developing therapies focusing on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities to influence KarXT (xanomeline–trospium) dominance.
• Other emerging products for schizophrenia and Alzheimer’s disease psychosis are expected to give tough market competition to KarXT (xanomeline–trospium), and the launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones and developmental activities provides the current development scenario of KarXT (xanomeline–trospium) in schizophrenia and Alzheimer’s disease psychosis.
• Our in-depth analysis of the forecasted sales data of KarXT (xanomeline–trospium) will support the clients in decision-making regarding their therapeutic portfolio by identifying the overall scenario of the KarXT (xanomeline–trospium) in schizophrenia and Alzheimer’s disease psychosis.

Key Questions

• What are the product type, route of administration, and mechanism of action of KarXT (xanomeline–trospium)?
• What is the clinical trial status of the study related to KarXT (xanomeline–trospium) in schizophrenia and Alzheimer’s disease psychosis, and the study completion date?
• What are the key collaborations, mergers and acquisitions, licensing, and other activities related to the KarXT (xanomeline–trospium) development?
• What are the regulatory milestones that KarXT (xanomeline–trospium) achieved for schizophrenia and Alzheimer’s disease psychosis?
• What is the forecasted market scenario of KarXT (xanomeline–trospium) for schizophrenia and Alzheimer’s disease psychosis?
• What are the forecasted sales of KarXT (xanomeline–trospium) in the seven major countries, including the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan? 
• What other emerging products are available, and how are these giving competition to KarXT (xanomeline–trospium) for schizophrenia and Alzheimer’s disease psychosis?
• Which are the late-stage emerging therapies under development for treating schizophrenia and Alzheimer’s disease psychosis?